var data={"title":"Mirabegron: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mirabegron: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/513991?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mirabegron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mirabegron: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15167819\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Myrbetriq</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617517\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Myrbetriq</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14585338\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Beta<sub>3</sub> Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965739\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Overactive bladder (OAB):</b> Oral: Initial: 25 mg once daily; efficacy is observed within 8 weeks for 25 mg dose. May increase to 50 mg once daily based on individual patient efficacy and tolerability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965740\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965741\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 to 89 mL/minute or eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 15 to 29 mL/minute or eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: Do not exceed 25 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;15 mL/minute or eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Not recommended (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965742\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (Child-Pugh class B): Do not exceed 25 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15167820\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myrbetriq: 25 mg, 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965578\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965840\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to food. Swallow the tablet whole with water; do not chew, divide, or crush.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14585330\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Overactive bladder:</b> Treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge urinary incontinence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15049289\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Cardiovascular: Hypertension (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4%), dizziness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (2% to 3%), xerostomia (3%), diarrhea (2%), abdominal pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3% to 6%), cystitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (3%), arthralgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (4%), sinusitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distension, angioedema (angioedema of the face, angioedema of the lips, angioedema of the throat, angioedema of the tongue with or without respiratory symptoms), anxiety, atrial fibrillation, bladder pain, blurred vision, breast cancer, cerebrovascular accident, confusion, dry eye syndrome, dyspepsia, gastritis, elevated gamma-glutamyl transferase, glaucoma, hallucination, increased lactate dehydrogenase, increased serum ALT, increased serum AST, insomnia, leukocytoclastic vasculitis, lip edema, malignant neoplasm of lung, malignant neoplasm of prostate, nausea, nephrolithiasis, osteoarthritis, palpitations, pruritus, purpura, rhinitis, skin rash, Stevens-Johnson syndrome, urinary retention, urticaria, vaginal infection, vulvovaginal pruritus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965591\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mirabegron or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Severe uncontrolled hypertension (systolic blood pressure &ge;180 mm Hg and/or diastolic blood pressure &ge;110 mm Hg); pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965598\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: Angioedema of the face, lips, tongue, and/or larynx has been reported; some cases have occurred after the first dose. May be life-threatening. Immediately discontinue and institute supportive care if the tongue, hypopharynx, or larynx is involved. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood pressure effects: Dose-related increases in blood pressure have been reported; monitor blood pressure periodically during therapy. Not recommended in patients with severe uncontrolled hypertension (SBP &ge;180 and/or DBP &ge;110 mm Hg); if used in patients with controlled and less severe hypertension, use with caution and monitor blood pressure closely; exacerbation of preexisting hypertension has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bladder flow obstruction: Use with caution in patients with bladder outlet obstruction (BOO); the risk of urinary retention may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; dosage adjustment is required in patients with moderate hepatic impairment. Use is not recommended in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Use with caution in patients with a history of QT interval prolongation or those receiving medications known to prolong the QT interval. In one thorough QT study, supratherapeutic doses prolonged the QTc interval based on the individual subject-specific correction method (QTcI) in females but not in males (Malik 2012). In general, mirabegron at the recommended dose has a low risk of QT interval prolongation (Sanford 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required in patients with severe renal impairment. Use is not recommended in ESRD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15163957\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15163955\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=85675&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Mirabegron.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desipramine: Mirabegron may increase the serum concentration of Desipramine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Mirabegron may increase the serum concentration of Digoxin.  Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron.  Monitor serum digoxin concentrations closely to help guide digoxin dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Mirabegron may increase the serum concentration of Flecainide.  Management: Monitor clinical response to flecainide closely.  Dose adjustment may be necessary.  Canadian mirabegron labeling recommends restricting the maximum adult mirabegron dose to 25 mg/day in patients receiving flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Mirabegron.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: Mirabegron may diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: Mirabegron may increase the serum concentration of Propafenone.  Management: Monitor clinical response to propafenone closely.  Dose adjustment may be necessary.  Canadian mirabegron labeling recommends restricting the maximum adult mirabegron dose to 25 mg/day in patients receiving propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Mirabegron.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solifenacin: Mirabegron may enhance the adverse/toxic effect of Solifenacin. Specifically, the risk of acute urinary retention may be enhanced. Mirabegron may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965618\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Coadministration with a high-fat meal decreased C<sub>max</sub> and AUC by 45% and 17%, respectively. Coadministration with a low-fat meal decreased C<sub>max</sub> and AUC by 75% and 51%, respectively. However, safety and efficacy were unaffected by food intake. Management: Mirabegron may be administered without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965584\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965585\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965590\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Mirabegron is expected to be excreted in breast milk. Because of the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965843\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood pressure at baseline and then periodically during therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965672\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mirabegron, a beta-3 adrenergic receptor agonist, activates beta-3 adrenergic receptors in the bladder resulting in relaxation of the detrusor smooth muscle during the urine storage phase, thus increasing bladder capacity. At usual doses, mirabegron is believed to display selectivity for the beta-3 adrenergic receptor subtype compared to its affinity for the beta-1 and -2 adrenoceptor subtypes. Data have shown that beta-adrenoceptors, predominately the beta-3 subtype, mediate detrusor smooth muscle tone and promote the storage function of the human bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965682\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Efficacy is seen within 8 weeks; steady state achieved within 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: ~1670 L (following IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~71%; binds mainly to albumin and alpha<sub>1</sub>-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive metabolism via multiple pathways (eg, dealkylation, oxidation, glucuronidation, amide hydrolysis) via multiple enzymes (eg, UGT, esterase, CYP3A4, CYP2D6); two major pharmacologically inactive metabolites produced</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 29% to 35% (following 25 mg and 50 mg oral dosing, respectively); bioavailability is dose-dependent; C<sub>max</sub> and AUC are higher in females compared to males</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~50 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (radiolabeled drug: 55%; unchanged drug: ~25%); feces (radiolabeled drug: 34%; unchanged drug: 0%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570442\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Myrbetriq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (90): $1,269.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $1,269.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14721653\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Betanis (JP);</li>\n      <li>Betmiga (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, ID, IE, IL, IS, LB, LT, LU, LV, MT, MY, NL, NO, PL, PT, RO, SE, SG, SI, SK, TH, TR);</li>\n      <li>Betmiga PR (KR);</li>\n      <li>Betmyha (UA);</li>\n      <li>Mirabeg (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. <i>Clin Pharmacol Ther</i>. 2012;92(6):696-706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/23149929/pubmed\" target=\"_blank\" id=\"23149929\">23149929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michel MC, Ochodnicky P, Homma Y, et al, &quot;&beta;-Adrenoceptor Agonist Effects in Experimental Models of Bladder Dysfunction,&quot; <i>Pharmacol Ther</i>, 2011, 131(1):40-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/21510978/pubmed\" target=\"_blank\" id=\"21510978\">21510978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myrbetriq (mirabegron) [prescribing information]. Northbrook, IL; Astellas Pharma; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myrbetriq (mirabegron) [product monograph]. Markham, ON, Canada: Astellas Pharma Canada Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanford M. Mirabegron: a review of its use in patients with overactive bladder syndrome. <i>Drugs</i>. 2013;73(11):1213-1225.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/23818156/pubmed\" target=\"_blank\" id=\"23818156\">23818156</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 85675 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15167819\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20617517\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14585338\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14965739\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14965740\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14965741\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14965742\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15167820\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14965578\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14965840\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14585330\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15049289\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14965591\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14965598\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F15163957\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15163955\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F14965618\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F14965584\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14965585\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14965590\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14965843\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14965672\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14965682\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570442\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14721653\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/85675|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mirabegron-patient-drug-information\" class=\"drug drug_patient\">Mirabegron: Patient drug information</a></li></ul></div></div>","javascript":null}